| Population 2015 |
54 million |
| |
| | | | | |
| Estimates of TB burden*, 2015 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
25 |
(21–29) |
46 |
(39–53) |
| Mortality (HIV+TB only) |
73 |
(27–140) |
133 |
(50–256) |
| Incidence (includes HIV+TB) |
454 |
(294–649) |
834 |
(539–1 190) |
| Incidence (HIV+TB only) |
258 |
(165–370) |
473 |
(303–680) |
| Incidence (MDR/RR-TB)** |
20 |
(13–27) |
37 |
(24–50) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2015 |
| |
0-14 years |
> 14 years |
Total |
| Females |
16 |
(6.9–25) |
175 |
(91–260) |
191 |
(98–285) |
| Males |
17 |
(9.8–23) |
246 |
(173–320) |
263 |
(182–343) |
| Total |
33 |
(21–44) |
422 |
(327–516) |
454 |
(294–649) |
| |
| | | | | |
| TB case notifications, 2015 |
|
| Total cases notified |
294 603 |
| Total new and relapse |
287 224 |
| - % tested with rapid diagnostics at time of diagnosis |
64% |
| - % with known HIV status |
97% |
| - % pulmonary |
90% |
| - % bacteriologically confirmed among pulmonary |
60% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2015 |
63% (44–98) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 |
0.22 (0.1–0.42) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2015 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
157 505 |
57% |
| - on antiretroviral therapy |
133 116 |
85% |
| |
| | | | | |
| Drug-resistant TB care, 2015 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
10 000
(8 200–12 000) |
| Estimated % of TB cases with MDR/RR-TB |
3.5% (2.8–4.2) |
7.1% (5.3–8.9) |
|
| % notified tested for rifampicin resistance |
65% |
71% |
196 783 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
7 402 |
| Laboratory-confirmed cases |
MDR/RR-TB: 19 613, XDR-TB: 1 024 |
| Patients started on treatment **** |
MDR/RR-TB: 12 527, XDR-TB: 730 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2014 |
78% |
319 752 |
| Previously treated cases, excluding relapse, registered in 2014 |
63% |
4 652 |
| HIV-positive TB cases, all types, registered in 2014 |
76% |
183 697 |
| MDR/RR-TB cases started on second-line treatment in 2013 |
48% |
10 614 |
| XDR-TB cases started on second-line treatment in 2013 |
24% |
611 |
| |
| | | | | |
| TB preventive treatment, 2015 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
38% |
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
|
| |
| | | | | |
| TB financing, 2016 |
|
| National TB budget (US$ millions) |
300 |
| Funding source: 81% domestic, 12% international, 7% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed | | |
| | | | | |